Certara, Inc. , a Radnor, Pennsylvania-based global leader in model-informed drug development, announced on September 29, 2026 the worldwide availability of Marvin Cloud, a browser-based, cloud-hosted chemical sketching platform built by the Chemaxon team on the Marvin cheminformatics engine. Chemaxon, a Budapest, Hungary-based cheminformatics company, has been a Certara subsidiary since 2024.
Adrian Stevens, Head of Product at Chemaxon, said: “Supporting scientific breakthroughs in chemistry is core to who we are, and for decades that’s meant putting professional-grade chemistry tools within reach of academic and research budgets, powering countless breakthroughs at the bench and in the classroom. Marvin Cloud carries that tradition forward for today’s researchers, giving individuals the same trusted Marvin our enterprise customers have been deploying with success for many years now.”
Enterprise Chemistry Tools, Sized for an Individual Budget
Marvin Cloud gives independent and academic scientists and students direct access to professional-grade structure drawing without needing institutional software deployment. Subscriptions are available globally, with secure payment support worldwide, and every new account starts with a 14-day free trial. The platform carries over core Marvin capabilities, including hotkey-driven workflows, publication-ready output, advanced polymer and Markush/R-group drawing, enumeration, precise stereochemistry handling, and chemical property calculations, and remains under active development with new features added on an ongoing basis.
The platform is structured around individual subscriptions with flexible pricing aimed at academic and independent researchers, teachers, and students; academic and not-for-profit institutions seeking broader deployment can still use the existing Chemaxon Academic Discount.
About Certara
Certara transforms drug discovery and development, helping scientists and clinical teams generate regulatory-grade evidence faster through solutions combining biosimulation, clinical intelligence, and regulatory science. Its clients include more than 2,600 biopharmaceutical companies, academic institutions, and global regulatory agencies.
